Physician profile
Troy B Gamble
NPI 1982662532
$1,798.97
in general payments reported to CMS, 2019-2025
29 companies · $424 in 2025
The $424 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $77.20 · 2021: $389 · 2022: $546 · 2023: $120 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $299.28 | 2022-2025 | |
| Abbvie INC. | $176.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $134.90 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $116.62 | 2019-2025 | Arexvy, Shingrix |
| Amgen INC. | $109.20 | 2019-2025 | Repatha, Otezla |
| Vital Connect, INC | $97.87 | 2022 | |
| Abbott Laboratories | $81.76 | 2021-2022 | |
| Mylan Specialty L.P. | $79.28 | 2019-2022 | |
| Lilly USA, LLC | $72.89 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.59 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $57.97 | 2021 | |
| Pfizer INC. | $56.03 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $49.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $42.58 | 2019 | |
| Novo Nordisk INC | $37.03 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.68 | 2021-2022 | |
| Genentech USA, INC. | $33.66 | 2019 | |
| Forte Bio-Pharma LLC | $29.56 | 2025 | Prolate, Nalocet, Tanlor |
| Sanofi-Aventis U.S. LLC | $27.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.90 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $24.40 | 2025 | Gemtesa |
| Viatris Specialty LLC | $23.63 | 2025 | Yupelri |
| Dexcom, INC. | $23.26 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.63 | 2019 | |
| Esperion Therapeutics, INC. | $21.03 | 2025 | Nexletol |
| Antares Pharma, INC. | $19.91 | 2025 | Xyosted |
| Organogenesis INC. | $15.25 | 2023 | Puraply |
| Exact Sciences Corporation | $15.12 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Gamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.